by San Rocco Therapeutics | Oct 15, 2015 | News
Streetwise Father Takes On Sloan Kettering to Save His Sick Son This is an article about the father of a Thalassemia patient who fights for his son. From his days as a troubled teenager on the gritty South Side of Chicago, Patrick Girondi has never shirked a fight....
by San Rocco Therapeutics | May 19, 2023 | News
Patrick Girondi, Renowned Artist, Lends Support to Robert F. Kennedy Jr. in Goal of Accessible Healthcare for Americans Patrick Girondi, CEO of San Rocco Therapeutics (SRT) met Wednesday, May 17, 2023 with Robert F. Kennedy Jr. who is running for the Democratic Party...
by San Rocco Therapeutics | May 5, 2023 | News
RICO Lawsuit against pharma bosses San Rocco Therapeutics filed an action for violations of federal RICO (Federal Racketeering and Corrupt Organizations Act), fraudulent inducement and unfair business practices in the United States District court for the District of...
by San Rocco Therapeutics | Mar 15, 2023 | News
SRT Prevails Against Bluebird Bio: American Arbitration Association After San Rocco Therapeutics (SRT) founder Patrick Girondi’s son was diagnosed with Thalassemia in 1992, Girondi founded SRT. The mission of SRT is to develop an accessible cure for Thalassemia and...
by San Rocco Therapeutics | Jan 27, 2023 | News
Patrick Girondi Responds to New York Times on the Corrupt Expenses of Gene Therapy The high prices are caused by corruption and out of control executive compensations. Even small start-up research companies without products are compensating their executives and boards...
by San Rocco Therapeutics | Jan 16, 2023 | News
Gene Therapy For Thalassemia Needs To Be Safer Insertional oncogenesis is an inherent risk of lentiviral vectors because they are able to integrate into thousands of loci within the genome. Bluebird’s Lenti-D integrated into 1 or more oncogenes in nearly all 67 trial...
by San Rocco Therapeutics | Sep 11, 2022 | News
LA Times Piece Glosses Over Gritty Realities Beta Thalassemia Gene Therapy: Bluebird Bio vs. San Rocco Therapeutics SRT gene therapy vector, since 2012, two out of three patients treated with myelosuppression and the SRT investigational product produced in 2009-2019...
by San Rocco Therapeutics | Sep 1, 2022 | News
TrialSite News: FDA Rejects Petition for Review of Gene Therapy Product for Safety Concerns Involving Vulnerable Patient Population Is the filing of a citizen petition with the U.S. Food and Drug Administration (FDA) an appropriate action for requesting review of a...
by San Rocco Therapeutics | Aug 29, 2022 | News
Informa: US FDA Quashes Citizen Petition Against Bluebird’s Zynteglo That Cited Patent, Safety Concerns San Rocco, whose potential rival gene therapy for thalassemia is in preclinical development, had wanted FDA to delay approval of bluebird’s BLA until resolution of...
by San Rocco Therapeutics | Aug 19, 2022 | News
Trialsite News: FDA Approves First Gene Therapy for Beta-Thalassemia Patients Who Require Regular Red Blood Cell Transfusions: $2.8m Cost Gene therapy-focused biotech venture bluebird bio announced recently that the U.S. Food and Drug Administration (FDA) approved...
by San Rocco Therapeutics | Jul 15, 2022 | News
EIN Presswire: Megan Euker, Acclaimed Project Manager, Wins Coveted Award SAN ROCCO THERAPEUTICS (SRT) Announces LOS ANGELES, CA, UNITED STATES, July 15, 2022 /EINPresswire.com/ — Megan Euker, acclaimed Project Manager, receives Fulbright U.S. Scholar Award to...
